MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ehf2.13406

Медицинская библиотека · ESC heart failure · 2021

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.

Hundertmark Moritz J, Agbaje Olorunsola F, Coleman Ruth, George Jyothis T, Grempler Rolf, Holman Rury R, Lamlum Hanan, Lee Jisoo, Milton Joanne E, Niessen Heiko G, Rider Oliver, Rodgers Christopher T, Valkovič Ladislav, Wicks Eleanor, Mahmod Masliza, Neubauer Stefan

СтатьяПоддержка исследования: вне правительства СШАПротокол клинического исследованияПеревод в очереди

Аннотация

AIMS: Despite substantial improvements over the last three decades, heart failure (HF) remains associated with a poor prognosis. The sodium-glucose co-transporter-2 inhibitor empagliflozin demonstrated significant reductions of HF hospitalization in patients with HF independent of the presence or absence of type 2 diabetes mellitus in the EMPEROR-Reduced trial and cardiovascular mortality in the EMPA-REG OUTCOME trial. To further elucidate the mechanisms behind these positive outcomes, this study aims to determine the effects of empagliflozin treatment on cardiac energy metabolism and physiology using magnetic resonance spectroscopy (MRS) and cardiovascular magnetic resonance (CMR).

METHODS AND

RESULTS

The EMPA-VISION trial is a double-blind, randomized, placebo-controlled, mechanistic study. A maximum of 86 patients with HF with reduced ejection fraction (n = 43, Cohort A) or preserved ejection fraction (n = 43, Cohort B), with or without type 2 diabetes mellitus, will be enrolled. Participants will be randomized 1:1 to receive either 10 mg of empagliflozin or placebo for 12 weeks. Eligible patients will undergo cardiovascular magnetic resonance, resting and dobutamine stress MRS, echocardiograms, cardiopulmonary exercise tests, serum metabolomics, and quality of life questionnaires at baseline and after 12 weeks. The primary endpoint will be the change in resting phosphocreatine-to-adenosine triphosphate ratio, as measured by 31 Phosphorus-MRS.

CONCLUSIONS

EMPA-VISION is the first clinical trial assessing the effects of empagliflozin treatment on cardiac energy metabolism in human subjects in vivo. The results will shed light on the mechanistic action of empagliflozin in patients with HF and help to explain the results of the safety and efficacy outcome trials (EMPEROR-Reduced and EMPEROR-Preserved).

Для цитирования: Hundertmark Moritz J, Agbaje Olorunsola F, Coleman Ruth, George Jyothis T, Grempler Rolf, Holman Rury R, Lamlum Hanan, Lee Jisoo, Milton Joanne E, Niessen Heiko G, Rider Oliver, Rodgers Christopher T, Valkovič Ladislav, Wicks Eleanor, Mahmod Masliza, Neubauer Stefan. Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.. ESC heart failure. 2021. DOI: 10.1002/ehf2.13406.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.